Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | CCR2 | P41597 | 5/20 | 0.46 |
| ▸ | HTR1A | P08908 | 4/20 | 0.46 |
| ▸ | DRD2 | P14416 | 4/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5386780 | 0.99 | OPRM1 (0.49) | OPRM1OPRK1OPRL1ADRA1DADRA1B | |
| SCHEMBL5396966 | 0.97 | OPRM1 (0.51) | OPRM1OPRK1OPRL1ADRA1DADRA1B | |
| SCHEMBL5396910 | 0.95 | OPRM1 (0.52) | OPRM1OPRK1OPRL1ADRA1DADRA1B | |
| SCHEMBL5384956 | 0.86 | CCR2 (0.47) | ADRA1DADRA1BCCR2HTR1ADRD2 | |
| SCHEMBL5385241 | 0.85 | CCR2 (0.48) | ADRA1DADRA1BCCR2HTR1ADRD2 | |
| SCHEMBL5388923 | 0.84 | OPRM1 (0.50) | OPRM1OPRK1OPRL1ADRA1DCCR2 | |
| SCHEMBL5384891 | 0.83 | ADRA1D (0.47) | ADRA1DADRA1BCCR2HTR1ADRD2 | |
| SCHEMBL5389020 | 0.83 | OPRM1 (0.49) | OPRM1OPRK1OPRL1ADRA1DCCR2 | |
| SCHEMBL5384939 | 0.83 | OPRM1 (0.59) | OPRM1OPRK1OPRL1ADRA1DCCR2 | |
| SCHEMBL5385140 | 0.83 | ADRA1D (0.58) | ADRA1DADRA1BCCR2HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1468996-B1 | Indole derivatives for the treatment of CNS disorders | LUNDBECK & CO AS H (DK) | 2007-09-26 | — | — | EP | claimed |
| US-6890916-B2 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2005-05-10 | — | — | US | claimed |
| EP-1468996-A1 | Indole derivatives for the treatment of CNS disorders | H. Lundbeck A/S (DK) | 2004-10-20 | — | — | EP | claimed |
| US-20030191133-A1 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2003-10-09 | — | — | US | claimed |
| EP-1294710-A1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2003-03-26 | — | — | EP | claimed |
| WO-2001096328-A1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2001-12-20 | — | — | WO | claimed |
| EP-1468996-B1 | Indole derivatives for the treatment of CNS disorders | LUNDBECK & CO AS H (DK) | 2007-09-26 | — | — | EP | disclosed |
| EP-1294710-B1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | LUNDBECK & CO AS H (DK) | 2005-06-08 | — | — | EP | disclosed |
| US-6890916-B2 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2005-05-10 | — | — | US | disclosed |
| EP-1468996-A1 | Indole derivatives for the treatment of CNS disorders | H. Lundbeck A/S (DK) | 2004-10-20 | — | — | EP | disclosed |
| US-20030191133-A1 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191133-A1 | Indole derivatives useful for the treatment of CNS disorders | TPH1, CHRM1, TPH2 | OPRM1 13/4885OPRK1 27/4885OPRL1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.